52,490	DUBUFFET ET AL.	
niner	Art Unit	
ael P. Barker	1626	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>12/22/05</u> .		
2. The allowed claim(s) is/are <u>5-8</u> .		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) □ All b) □ Some* c) □ None of the:  1. □ Certified copies of the priority documents have been received.  2. □ Certified copies of the priority documents have been received in Application No  3. □ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  4. □ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.  5. □ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.  (a) □ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached  1) □ hereto or 2) □ to Paper No./Mail Date  (b) □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).  5. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
6. ☐ Interview Summary Paper No./Mail Dat 7. ☐ Examiner's Amendn	(PTO-413), te nent/Comment	owance
	EMAINS) CLOSED in this apper appropriate communication. This application is subject to IPEP 1308.  5 U.S.C. § 119(a)-(d) or (f).  received. received in Application No ts have been received in this  communication to file a reply of this application.  Note the attached EXAMINER con(s) why the oath or declarate ubmitted. atent Drawing Review (PTO- adment / Comment or in the Condition of the drawing der according to 37 CFR 1.121(a)  BIOLOGICAL MATERIAL in THE DEPOSIT OF BIOLOGICAL MATERIAL in THE DEPOSIT OF BIOLOGICAL CONTROL OF BIOLOGICAL MATERIAL in THE DEPOSIT OF BIOLOGICAL CONTROL OF	nther and P. Barker 1626  In the cover sheet with the correspondence address and the cover sheet with the application. If not include a appropriate communication will be mailed in due. This application is subject to withdrawal from issuance in the cover sheet and the c

Application/Control Number: 10/562,490

Art Unit: 1626

## **DETAILED ACTION**

Claims 7-15 are pending and in condition for allowance.

## Information Disclosure Statement

The information disclosure statements (IDS) submitted on December 22, 2005 and June 15, 2006 were correctly filed. The submissions are in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS's were considered by the Examiner. Please refer to Applicant's copies of PTO-1449, submitted herewith.

## Reasons for Allowance

Applicant's invention is drawn to a process for preparing perindopril and its pharmaceutically acceptable salts. Preparation and use of perindopril was described in European Patent No. 0049658 A1, issued April 14, 1982. However, the synthesis disclosed in the '658 patent is similar to Applicant's claimed invention in that the end products are identical. The closest art of record is Applicant's own invention disclosed in US Patent Publication No. 2005171165 A1, published July 4, 2005. The '165 publication does not follow the same reaction mechanism and therefore does not meet all of the limitations of the instant application.

Because there is no prior art which meets each limitation of the instant claims or which renders the instant claims obvious, Claims 5-8 are ALLOWED.

Application/Control Number: 10/562,490 Page 3

Art Unit: 1626

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Michael P. Barker whose telephone number is (571) 272-4341.

The examiner can normally be reached on Monday-Friday 8:00 AM- 5:00 PM. If attempts to

reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K.

McKane, can be reached at (571) 272-0699. The unofficial fax phone for this group are (571)

273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is viable through Private PAIR only. For more information about the PAIR system,

see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael P. Barker

Patent Examiner, AU 1626

KAMAL A. SAEED, PH.D. PRIMARY EXAMINER

(for) Joseph McKane

Supervisory Patent Examiner, AU 1626